Clinical trials
Locally Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting locally advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 4,340 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05443126RecruitingPhase 1/Phase 2
Testing a new RET drug for advanced lung cancer
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06342336RecruitingPhase 1
HS-IT101 injection for advanced solid tumors
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT07169552RecruitingPhase 2
HC010 for first-line PD-L1 positive advanced lung cancer
This trial tests a new drug called HC010 as a first treatment for people with advanced non-small cell lung cancer that is PD-L1 positive. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07670013RecruitingPhase 2
SKB264 and glecirasib for advanced KRAS G12C lung cancer
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Hangzhou, ZhejiangAges 18–75 - NCT07207707RecruitingPhase 1
KQB548 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06014827RecruitingPhase 2
Targeted radiation and osimertinib for lung cancer with EGFR mutation
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
Duarte, CaliforniaAges 18 years+ - NCT06703398RecruitingPhase 2
Study of GC101 TIL for advanced melanoma
This trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. It involves taking immune cells from a tumor, growing them in a lab, and giving them back to fight the cancer.
BeijingAges 18–75 - NCT07227402RecruitingPhase 3
Study of belzutifan and zanzalintinib for recurrent kidney cancer
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Anchorage, AlaskaAges 18 years+ - NCT06995677RecruitingPhase 2
TYRA-300 pill for low-grade bladder cancer with FGFR3 change
This study tests an experimental pill called TYRA-300 for people with low-grade bladder cancer that hasn't spread into the muscle layer. The pill targets a specific gene change (FGFR3) found in the tumor. The goal is to see if it can slow or shrink the cancer.
Homewood, AlabamaAges 18 years+ - NCT07402343RecruitingPhase 2
Tarlatamab for small cell lung cancer brain metastases
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
AmsterdamAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT02029001RecruitingPhase 2
Personalized treatment matched to your tumor’s DNA changes
This Phase 2 study tests whether choosing cancer drugs based on specific DNA or blood test results from your tumor can work better for people with advanced solid tumors. It aims to use a molecular tumor board’s recommendation to guide the safest, most likely targeted treatment for each patient.
BordeauxAges 18 years+ - NCT06081920RecruitingPhase 2
IBI363 for advanced melanoma after standard treatment
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07255404RecruitingPhase 2
Testing pumitamig with chemotherapy for untreated pancreatic cancer
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
Bedford ParkAges 18 years+ - NCT06987058Enrolling by invitationPhase 2
Continued RVU120 treatment study for current participants
This trial is for people who are already in a RVU120 study and have been receiving the drug for at least 5 cycles. It allows you to keep getting RVU120 if you are benefiting from it and don't have other treatment options.
GdanskAges 18 years+ - NCT07089992RecruitingPhase 2
Pembrolizumab for ultra-rare sarcoma types
This trial tests whether pembrolizumab, an immunotherapy that helps your immune system attack cancer cells, can shrink or slow growth in several ultra-rare sarcoma types that have come back or spread. It may be an option if your previous treatments have stopped working.
Basking Ridge, New JerseyAges 18 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
Tucson, ArizonaAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT05719558RecruitingPhase 1
Study of ASP1002 for adults with solid tumors
This trial tests a new drug called ASP1002, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if ASP1002 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT05957367RecruitingPhase 1/Phase 2
Study drug for advanced GIST tumors with specific gene mutations
This early-phase study tests inlexisertib (a targeted cancer drug) combined with other anticancer treatments in adults with advanced GIST. It is mainly looking for safety and the best way to dose, and it may help tumors that have certain KIT or PDGFRA gene changes.
Los Angeles, CaliforniaAges 18 years+ - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
DoradoAges 18 years+ - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 4,340 recruiting locally advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced/Metastatic Breast Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Advanced or Metastatic Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.